-
Je něco špatně v tomto záznamu ?
Extracellular AGR3 regulates breast cancer cells migration via Src signaling
J. Obacz, L. Sommerova, D. Sicari, M. Durech, T. Avril, F. Iuliano, S. Pastorekova, R. Hrstka, E. Chevet, F. Delom, D. Fessart,
Jazyk angličtina Země Řecko
Typ dokumentu časopisecké články
NLK
PubMed Central
od 2010
ProQuest Central
od 2012-01-01
Health & Medicine (ProQuest)
od 2012-01-01
PubMed
31611954
DOI
10.3892/ol.2019.10849
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
Human anterior gradient proteins AGR2 and AGR3 are overexpressed in a variety of adenocarcinomas and are often secreted in cancer patients' specimens, which suggests a role for AGR proteins in intra and extracellular compartments. Although these proteins exhibit high sequence homology, AGR2 is predominantly described as a pro-oncogene and a potential prognostic biomarker. However, little is known about the function of AGR3. Therefore, the aim of the present study was to investigate the role of AGR3 in breast cancer. The results demonstrated that breast cancer cells secrete AGR3. Furthermore, it was revealed that extracellular AGR3 (eAGR3) regulates tumor cell adhesion and migration. The current study indicated that the pharmacological and genetic perturbation of Src kinase signaling, through treatment with Dasatinib (protein kinase inhibitor) or investigating cells that express a dominant-negative form of Src, significantly abrogated eAGR3-mediated breast cancer cell migration. Therefore, the results indicated that eAGR3 may control tumor cell migration via activation of Src kinases. The results of the present study indicated that eAGR3 may serve as a microenvironmental signaling molecule in tumor-associated processes.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19044218
- 003
- CZ-PrNML
- 005
- 20200109095610.0
- 007
- ta
- 008
- 200107s2019 gr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3892/ol.2019.10849 $2 doi
- 035 __
- $a (PubMed)31611954
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Obacz, Joanna $u INSERM U1242, 'Chemistry, Oncogenesis Stress Signaling', University of Rennes Campus 1, F-35000 Rennes, France. Centre de Lutte Contre le Cancer Eugène Marquis, F-35000 Rennes, France. Masaryk Memorial Cancer Institute, RECAMO, 656 53 Brno, Czech Republic. Institute of Virology, Biomedical Research Center, Slovak Academy of Sciences, 845 05 Bratislava, Slovak Republic.
- 245 10
- $a Extracellular AGR3 regulates breast cancer cells migration via Src signaling / $c J. Obacz, L. Sommerova, D. Sicari, M. Durech, T. Avril, F. Iuliano, S. Pastorekova, R. Hrstka, E. Chevet, F. Delom, D. Fessart,
- 520 9_
- $a Human anterior gradient proteins AGR2 and AGR3 are overexpressed in a variety of adenocarcinomas and are often secreted in cancer patients' specimens, which suggests a role for AGR proteins in intra and extracellular compartments. Although these proteins exhibit high sequence homology, AGR2 is predominantly described as a pro-oncogene and a potential prognostic biomarker. However, little is known about the function of AGR3. Therefore, the aim of the present study was to investigate the role of AGR3 in breast cancer. The results demonstrated that breast cancer cells secrete AGR3. Furthermore, it was revealed that extracellular AGR3 (eAGR3) regulates tumor cell adhesion and migration. The current study indicated that the pharmacological and genetic perturbation of Src kinase signaling, through treatment with Dasatinib (protein kinase inhibitor) or investigating cells that express a dominant-negative form of Src, significantly abrogated eAGR3-mediated breast cancer cell migration. Therefore, the results indicated that eAGR3 may control tumor cell migration via activation of Src kinases. The results of the present study indicated that eAGR3 may serve as a microenvironmental signaling molecule in tumor-associated processes.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Sommerova, Lucia $u Masaryk Memorial Cancer Institute, RECAMO, 656 53 Brno, Czech Republic.
- 700 1_
- $a Sicari, Daria $u INSERM U1242, 'Chemistry, Oncogenesis Stress Signaling', University of Rennes Campus 1, F-35000 Rennes, France.
- 700 1_
- $a Durech, Michal $u Masaryk Memorial Cancer Institute, RECAMO, 656 53 Brno, Czech Republic.
- 700 1_
- $a Avril, Tony $u INSERM U1242, 'Chemistry, Oncogenesis Stress Signaling', University of Rennes Campus 1, F-35000 Rennes, France. Centre de Lutte Contre le Cancer Eugène Marquis, F-35000 Rennes, France.
- 700 1_
- $a Iuliano, Filippo $u Institute of Virology, Biomedical Research Center, Slovak Academy of Sciences, 845 05 Bratislava, Slovak Republic.
- 700 1_
- $a Pastorekova, Silvia $u Masaryk Memorial Cancer Institute, RECAMO, 656 53 Brno, Czech Republic. Institute of Virology, Biomedical Research Center, Slovak Academy of Sciences, 845 05 Bratislava, Slovak Republic.
- 700 1_
- $a Hrstka, Roman $u Masaryk Memorial Cancer Institute, RECAMO, 656 53 Brno, Czech Republic.
- 700 1_
- $a Chevet, Eric $u INSERM U1242, 'Chemistry, Oncogenesis Stress Signaling', University of Rennes Campus 1, F-35000 Rennes, France. Centre de Lutte Contre le Cancer Eugène Marquis, F-35000 Rennes, France.
- 700 1_
- $a Delom, Frederic $u University of Bordeaux, ACTION, F-33000 Bordeaux, France. INSERM U1218, F-33000 Bordeaux, France. Bergonie Cancer Institute, F-33000 Bordeaux, France.
- 700 1_
- $a Fessart, Delphine $u INSERM U1242, 'Chemistry, Oncogenesis Stress Signaling', University of Rennes Campus 1, F-35000 Rennes, France. Centre de Lutte Contre le Cancer Eugène Marquis, F-35000 Rennes, France. University of Bordeaux, ACTION, F-33000 Bordeaux, France. INSERM U1218, F-33000 Bordeaux, France.
- 773 0_
- $w MED00193499 $t Oncology letters $x 1792-1074 $g Roč. 18, č. 5 (2019), s. 4449-4456
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31611954 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200107 $b ABA008
- 991 __
- $a 20200109095939 $b ABA008
- 999 __
- $a ind $b bmc $g 1480807 $s 1082888
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 18 $c 5 $d 4449-4456 $e 20190910 $i 1792-1074 $m Oncology letters $n Oncol Lett $x MED00193499
- LZP __
- $a Pubmed-20200107